Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fc gamma receptor III.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  JIM - Journal of Immunological Methods

• Publication date

  1995-08-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0022-1759(95)00095-RPMID 7658026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fc receptor-mediated signal transduction

  2005cited by this paper
• [Receptor-mediated signal transduction].

  1996cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.

  1994cited by this paper
• The biology and pathology of Fc receptors

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

  1993cited by this paper
• Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

  1993cited by this paper
• Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

  1993cited by this paper
• Endocytosis of glycophospholipid‐anchored and transmembrane forms of CD4 by different endocytic pathways.

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes.

  1992cited by this paper
• Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.

  1991cited by this paper
• Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.

  1991cited by this paper
• Glycolipid anchoring of plasma membrane proteins.

  1990cited by this paper
• Biosynthesis of glycosyl phosphatidylinositol membrane anchors.

  1990cited by this paper
• PROLONGATION OF RED‐CELL LIFE‐SPAN BY INCORPORATION OF DECAY‐ACCELERATING FACTOR (DAF) INTO RED CELLS OF PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH)

  1989cited by this paper
• Internalization of phosphatidylinositol-anchored lymphocyte proteins. I. Documentation and potential significance for T cell stimulation.

  1989cited by this paper
• Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures.

  1988cited by this paper
• Glycosyl-phosphatidylinositol moiety that anchors Trypanosoma brucei variant surface glycoprotein to the membrane.

  1988cited by this paper
• Structural and functional roles of glycosyl-phosphatidylinositol in membranes.

  1988cited by this paper
• The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria

  1988cited by this paper
• Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor

  1987cited by this paper
• Thy-1 functions as a signal transduction molecule in T lymphocytes and transfected B lymphocytes

  1986cited by this paper
• Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.

  1985cited by this paper
• Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes

  1984cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• (Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins II: Intercellular Transfer of Matter (Inheritance?) That Matters

  2023cites this paper
• Biological Role of the Intercellular Transfer of Glycosylphosphatidylinositol-Anchored Proteins: Stimulation of Lipid and Glycogen Synthesis

  2022cites this paper
• Interaction of Full-Length Glycosylphosphatidylinositol-Anchored Proteins with Serum Proteins and Their Translocation to Cells In Vitro Depend on the (Pre-)Diabetic State in Rats and Humans

  2021cites this paper
• Chip-Based Sensing of the Intercellular Transfer of Cell Surface Proteins: Regulation by the Metabolic State

  2021cites this paper
• Membrane insertion and intercellular transfer of glycosylphosphatidylinositol-anchored proteins: potential therapeutic applications

  2018cites this paper
• Effects of anchor structure and glycosylation of Fcγ receptor III on ligand binding affinity

  2016cites this paper
• Effects of Anchor Structure and Glycosylation of FcÎ 3 Receptor III on Ligand Binding Affinity Ning

  2016cites this paper
• Semisynthesis of membrane-anchored cholesteryl lipoproteins on live cell surface by azide–alkyne click reaction

  2016cites this paper
• vwF A3-GPI modification of EPCs accelerates reendothelialization of injured vessels via collagen targeting in mice

  2016cites this paper
• Biomedical applications of glycosylphosphatidylinositol-anchored proteins

  2016cites this paper
• Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy

  2015cites this paper
• Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non‐Hodgkin's Lymphoma

  2014cites this paper
• Texosome-anchored superantigen triggers apoptosis in original ovarian cancer cells

  2014cites this paper
• Lipid-Mediated Cell Surface Engineering

  2014cites this paper
• Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development

  2012cites this paper
• Synthetic cell surface receptors for delivery of therapeutics and probes.

  2012cites this paper
• Immune Surveillance and Tumor Evasion

  2011cites this paper
• Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology

  2011cites this paper
• A novel vWF A3-GPI modified EPCs to enhance its adhesion ability to collegen

  2011cites this paper
• Surface Engineering of Biomembranes with GPI-Anchored Proteins and its Applications

  2010cites this paper
• Cancer vaccine development: designing tumor cells for greater immunogenicity.

  2010cites this paper
• Surface engineering of microparticles by novel protein transfer for targeted antigen/drug delivery.

  2009cites this paper
• Endocytosis: Receptor-Mediated

  2008cites this paper
• Custom designing therapeutic cancer vaccines: Delivery of immunostimulatory molecule adjuvants by protein transfer

  2008cites this paper
• Membrane reinsertion of a myristoyl-peptidyl anchored extracellular domain growth hormone receptor.

  2007cites this paper
• Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes

  2007cites this paper
• Modified cell ELISA to determine the solubilization of cell surface proteins: Applications in GPI-anchored protein purification.

  2005cites this paper
• Synthetic mimics of mammalian cell surface receptors: prosthetic molecules that augment living cells.

  2005cites this paper
• Differential insertion of GPI‐anchored GFPs into lipid rafts of live cells

  2005cites this paper
• The α vβ 3 integrin as a tumor homing ligand for lymphocytes

  2004cites this paper
• Cancer vaccine development

  2004cites this paper
• GPI-anchoring of GM-CSF results in active membrane-bound and partially shed cytokine.

  2002cites this paper
• Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules.

  2001cites this paper
• Designer cancer vaccines made easy: protein transfer of immunostimulatory molecules for use in therapeutic tumor vaccines.

  2001influential citation
• The GPI-anchor and protein sorting

  2001cites this paper
• Quantifying the Impact of Membrane Microtopology on Effective Two-dimensional Affinity* 210

  2001cites this paper
• Properties of exogenously added GPI‐anchored proteins following their incorporation into cells *

  2001cites this paper
• Glycerolphosphoinositide anchors for membrane-tethering proteins.

  2000cites this paper
• Expression and characterization of glycolipid-anchored B7-1 (CD80) from baculovirus-infected insect cells: protein transfer onto tumor cells.

  1999cites this paper
• Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy.

  1999cites this paper
• Cell‐surface engineering with GPI‐anchored proteins

  1996cites this paper
• Transfer of exogenous glycosylphos-phatidylinositol (GPI)-linked molecules to plasma membranes.

  1996cites this paper